Recursion Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Recursion PharmaceuticalsDer Gewinn des Unternehmens wird voraussichtlich um 8% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 20.3% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich wachsen um 1.2% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -125.4% betragen.

Wichtige Informationen

-7.6%

Wachstumsrate der Gewinne

2.2%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.4%
Wachstumsrate der Einnahmen	20.3%
Zukünftige Eigenkapitalrendite	-168.1%
Analystenabdeckung	Good
Zuletzt aktualisiert	09 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Earnings Beat: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Aug 12

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

May 12

Recent updates

Recursion: AI Is Only As Good As The Data

Sep 11

Recursion: Path Forward For REC-994 Remains Despite Mixed Response

Sep 04

Earnings Beat: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Aug 12

Revenues Not Telling The Story For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) After Shares Rise 25%

May 22

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

May 12

Revisiting Recursion: Big Bets, Big Data, And The Big Cash Burn Rate

Apr 10

Recursion: Exercising Caution Prior To Q3 Data Release (Rating Downgrade)

Mar 20

Recursion Pharmaceuticals (NASDAQ:RXRX) Is Using Debt Safely

Jan 31

Recursion Pharmaceuticals: More Hype Than Substance Amid Signs Of Progress

Jan 12

Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) 45% Price Boost Is Out Of Tune With Revenues

Dec 09

What You Need To Know About The Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Analyst Downgrade Today

May 09

We Think Recursion Pharmaceuticals (NASDAQ:RXRX) Can Easily Afford To Drive Business Growth

Mar 01

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:RXRX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	100	-347	-221	-270	4
12/31/2025	60	-476	-365	-337	8
12/31/2024	69	-404	-311	-298	9
6/30/2024	50	-375	-346	-332	N/A
3/31/2024	46	-354	-331	-317	N/A
12/31/2023	45	-328	-300	-288	N/A
9/30/2023	47	-293	-277	-258	N/A
6/30/2023	50	-260	-266	-240	N/A
3/31/2023	47	-249	-273	-234	N/A
12/31/2022	40	-239	-121	-84	N/A
9/30/2022	29	-247	-134	-100	N/A
6/30/2022	18	-234	-113	-78	N/A
3/31/2022	13	-212	-75	-50	N/A
12/31/2021	10	-186	-198	-159	N/A
9/30/2021	10	-147	-129	-89	N/A
6/30/2021	9	-124	-106	-75	N/A
3/31/2021	6	-99	-84	-58	N/A
12/31/2020	4	-87	-52	-45	N/A
12/31/2019	2	-62	-61	-57	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: RXRX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: RXRX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: RXRX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: RXRXDie Einnahmen des Unternehmens (20.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.8% pro Jahr).

Hohe Wachstumseinnahmen: RXRXDie Einnahmen des Unternehmens (20.3% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: RXRX wird voraussichtlich in 3 Jahren unrentabel sein.

Recursion Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Earnings Beat: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Price target decreased by 11% to US$11.57

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

Price target decreased by 23% to US$12.33

Consensus EPS estimates fall by 18%

Price target decreased by 10.0% to US$14.86

Recent updates

Recursion: AI Is Only As Good As The Data

Co-Founder exercised options and sold US$244k worth of stock

Recursion: Path Forward For REC-994 Remains Despite Mixed Response

Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability

Earnings Beat: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Co-Founder notifies of intention to sell stock

Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) entered into a transaction agreement to acquire Exscientia plc (NasdaqGS:EXAI) for approximately $640 million.

Recursion Pharmaceuticals, Inc. Announces to Appoint David Hallett, Ph.D as Chief Scientific Officer

Recursion Pharmaceuticals: AI-Driven 'TechBio' With Upcoming Catalysts

Co-Founder notifies of intention to sell stock

Price target decreased by 11% to US$11.57

Recursion Pharmaceuticals, Inc.(NasdaqGS:RXRX) dropped from Russell 3000E Value Index

Recursion Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $199.999995 million.

Recursion Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $199.999995 million.

Recursion Pharmaceuticals: More Of A TechBio Industrializing Drug Discovery

Recursion Pharmaceuticals: Catalysts Are Coming And Success Is A Must

Co-Founder notifies of intention to sell stock

Revenues Not Telling The Story For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) After Shares Rise 25%

Recursion Announces Completion of NVIDIA-Powered BioHive-2

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Co-Founder notifies of intention to sell stock

Recursion Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 09, 2024

Chief Financial Officer exercised options and sold US$260k worth of stock

Recursion Appoints Najat Khan as Chief R&D Officer and Chief Commercial Officer

Revisiting Recursion: Big Bets, Big Data, And The Big Cash Burn Rate

Co-Founder notifies of intention to sell stock

Recursion: Exercising Caution Prior To Q3 Data Release (Rating Downgrade)

Co-Founder & Director notifies of intention to sell stock

Co-Founder & Director notifies of intention to sell stock

Recursion Pharmaceuticals, Inc. Appoints Kristen Rushton as Chief Business Operations Officer

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Recursion Pharmaceuticals, Inc., Annual General Meeting, Jun 03, 2024

Recursion Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Recursion Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Co-Founder notifies of intention to sell stock

Recursion Pharmaceuticals, Inc. Announces Transition of Shafique Virani from the Chief Business Officer into Senior Strategic Advisor

Recursion Pharmaceuticals (NASDAQ:RXRX) Is Using Debt Safely

Recursion Pharmaceuticals: More Hype Than Substance Amid Signs Of Progress

Recursion Unveils Lowe Drug Discovery Software At the J.P. Morgan Healthcare Conference

Co-Founder notifies of intention to sell stock

Price target decreased by 23% to US$12.33

Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) 45% Price Boost Is Out Of Tune With Revenues

Co-Founder notifies of intention to sell stock

Chief Financial Officer exercised options and sold US$266k worth of stock

Consensus EPS estimates fall by 18%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Recursion Pharmaceuticals, Inc. Announces Completion of Phase 1 Study for Rec-3964 for Clostridioides Difficile Infection

Chief Financial Officer notifies of intention to sell stock

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Independent Director notifies of intention to sell stock

Recursion Pharmaceuticals, Inc. announced that it has received $50.000001 million in funding from NVIDIA Corporation

New major risk - Share price stability

Recursion Announces Phase 2 Trial for the Treatment of Cerebral Cavernous Malformation Has Fully Enrolled

Co-Founder & Director notifies of intention to sell stock

Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) completed the acquisition of Cyclica Inc.

Recursion Pharmaceuticals, Inc. Appoints David Mauro as Chief Medical Officer

Price target decreased by 10.0% to US$14.86

Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) entered into a Share Purchase Agreement to acquire Valence Discovery for $47.5 million.

First quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) entered into a Share Purchase Agreement to acquire Cyclica Inc. for $40 million.

What You Need To Know About The Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Analyst Downgrade Today

Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) entered into a Share Purchase Agreement to acquire Valence Discovery for $47.5 million.

Co-Founder notifies of intention to sell stock

Co-Founder & Director notifies of intention to sell stock

Co-Founder & Director notifies of intention to sell stock

Co-Founder & Director notifies of intention to sell stock